Y's Therapeutics Clinical-Stage Compound YSPSL Granted Orphan Status In U.S. And Europe

... Y's Therapeutics, Inc. saidtoday that the U.S. Food and Drug Administration (FDA) and the EuropeanMedicines Evaluation Agency (EMEA) have granted Orphan Drug Designation and Orphan Medicinal Product Designation, respectively, for its investigationaldrug YSPSL (rPSGL-Ig) in the prevention of graft dysfunction in kidneytransplantation. [click link for full article] ...